Position in AKTS
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$5,188,100
New position
Shares Held
290,000
first reported quarter
Ownership
0.525%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Mar 31, 2026Alyeska Investment Group, L.P. holds $1,219,709,732 across 81 Biotechnology names. AKTS ranks #44 (0.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | MRNA |
Moderna, Inc.
|
4,051,185 | $205,800,198 | |
| 2 | RVMD |
Revolution Medicines, Inc.
|
1,885,821 | $183,396,092 | |
| 3 | JAZZ |
Jazz Pharmaceuticals plc
|
411,015 | $77,702,385 | |
| 4 | XENE |
Xenon Pharmaceuticals Inc.
|
1,299,469 | $75,564,122 | |
| 5 | PTGX |
Protagonist Therapeutics, Inc
|
593,197 | $62,522,963 | |
| 6 | DNLI |
Denali Therapeutics Inc.
|
1,941,123 | $37,269,561 | |
| 7 | IONS |
Ionis Pharmaceuticals Inc
|
473,150 | $35,528,833 | |
| 8 | TECH |
BIO-TECHNE Corp
|
659,049 | $34,441,900 |
All Filings in AKTS
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $5,188,100 | 290,000 | Shares | Sole | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||